$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

$cpix Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000162828017011224 Filed on November 08, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$11.65M	$11.20M	$9.081M
YoY Change	28.28%	27.36%	12.99%
Cost Of Revenue	$2.150M	$2.166M	$1.610M
YoY Change	33.54%	9.75%	1.26%
Gross Profit	$9.500M	$9.031M	$7.480M
YoY Change	27.01%	32.46%	15.97%
Gross Profit Margin	81.55%	80.65%	82.37%
Selling, General & Admin	$8.790M	$8.317M	$6.710M
YoY Change	31.0%	51.77%	24.95%
% of Gross Profit	92.53%	92.1%	89.71%
Research & Development	$980.0K	$943.2K	$1.160M
YoY Change	-15.52%	46.3%	190.0%
% of Gross Profit	10.32%	10.44%	15.51%
Depreciation & Amortization	$680.0K	$660.0K	$610.0K
YoY Change	11.48%	6.45%	7.02%
% of Gross Profit	7.16%	7.31%	8.16%
Operating Expenses	$10.40M	$9.260M	$8.430M
YoY Change	23.37%	51.19%	34.24%
Operating Profit	-$903.3K	-$839.3K	-$957.4K
YoY Change	-5.65%	-745.0%	-688.5%
Interest Expense	$60.00K	$8.902K	$20.00K
YoY Change	200.0%	-69.4%	100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$840.0K	-$753.4K	-$940.0K
YoY Change	-10.64%	-593.46%	-652.94%
Income Tax	$80.00K	$3.822K	-$170.0K
% Of Pretax Income
Net Earnings	-$800.5K	-$743.0K	-$749.7K
YoY Change	6.78%	-799.88%	-596.29%
Net Earnings / Revenue	-6.87%	-6.64%	-8.26%
Basic Earnings Per Share	-$0.05	-$0.05	-$0.05
Diluted Earnings Per Share	-$0.05	-$0.05	-$0.05
COMMON SHARES
Basic Shares Outstanding	15.75M shares	15.87M shares	16.18M shares
Diluted Shares Outstanding		15.87M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.09M	$50.07M	$50.13M
YoY Change	-0.09%	-0.14%	-4.99%
Cash & Equivalents	$45.41M	$42.02M	$34.51M
Short-Term Investments	$4.672M	$8.055M	$15.62M
Other Short-Term Assets	$3.467M	$2.946M	$2.711M
YoY Change	27.87%	-42.92%	-32.19%
Inventory	$6.738M	$5.857M	$5.372M
Prepaid Expenses
Receivables	$8.395M	$7.205M	$7.330M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$68.68M	$66.08M	$65.55M
YoY Change	4.79%	-1.31%	1.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$528.9K	$474.7K	$464.5K
YoY Change	13.87%	-1.63%	-13.42%
Goodwill	$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.487M	$2.253M	$2.121M
YoY Change	17.26%	-8.26%	12.15%
Total Long-Term Assets	$24.55M	$24.27M	$27.86M
YoY Change	-11.89%	0.65%	1.92%
TOTAL ASSETS
Total Short-Term Assets	$68.68M	$66.08M	$65.55M
Total Long-Term Assets	$24.55M	$24.27M	$27.86M
Total Assets	$93.23M	$90.35M	$93.40M
YoY Change	-0.18%	-0.79%	1.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.980M	$7.922M	$8.037M
YoY Change	11.74%	18.98%	179.29%
Accrued Expenses	$8.715M		$6.756M
YoY Change	29.0%		-29.14%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.69M	$15.80M	$14.79M
YoY Change	19.62%	35.19%	19.18%
LONG-TERM LIABILITIES
Long-Term Debt	$9.800M	$8.000M	$4.100M
YoY Change	139.02%	116.22%	141.18%
Other Long-Term Liabilities	$1.816M	$1.600M	$1.391M
YoY Change	30.51%	23.08%	40.92%
Total Long-Term Liabilities	$1.816M	$9.600M	$1.391M
YoY Change	30.51%	92.0%	40.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.69M	$15.80M	$14.79M
Total Long-Term Liabilities	$1.816M	$9.600M	$1.391M
Total Liabilities	$29.31M	$25.43M	$20.28M
YoY Change	44.5%	52.74%	34.34%
SHAREHOLDERS EQUITY
Retained Earnings	$11.71M	$12.51M	$18.60M
YoY Change	-37.06%	-35.37%	-4.83%
Common Stock	$52.41M	$52.59M	$54.64M
YoY Change	-4.09%	-4.69%	-4.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$64.12M	$65.10M	$73.25M
YoY Change
Total Liabilities & Shareholders Equity	$93.23M	$90.35M	$93.40M
YoY Change	-0.18%	-0.79%	1.62%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$800.5K	-$743.0K	-$749.7K
YoY Change	6.78%	-799.88%	-596.29%
Depreciation, Depletion And Amortization	$680.0K	$660.0K	$610.0K
YoY Change	11.48%	6.45%	7.02%
Cash From Operating Activities	-$460.0K	$990.0K	$820.0K
YoY Change	-156.1%	241.38%	-38.35%
INVESTING ACTIVITIES
Capital Expenditures	-$480.0K	-$110.0K	-$480.0K
YoY Change	0.0%	-78.0%	128.57%
Acquisitions
YoY Change
Other Investing Activities	$3.380M	$6.340M	-$1.010M
YoY Change	-434.65%	-31800.0%	676.92%
Cash From Investing Activities	$2.910M	$6.210M	-$1.500M
YoY Change	-294.0%	-1294.23%	354.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	940.0K	200.0K	-360.0K
YoY Change	-361.11%	-385.71%	-66.97%
NET CHANGE
Cash From Operating Activities	-460.0K	990.0K	820.0K
Cash From Investing Activities	2.910M	6.210M	-1.500M
Cash From Financing Activities	940.0K	200.0K	-360.0K
Net Change In Cash	3.390M	7.400M	-1.040M
YoY Change	-425.96%	-2566.67%	1055.56%
FREE CASH FLOW
Cash From Operating Activities	-$460.0K	$990.0K	$820.0K
Capital Expenditures	-$480.0K	-$110.0K	-$480.0K
Free Cash Flow	$20.00K	$1.100M	$1.300M
YoY Change	-98.46%	39.24%	-15.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21950	shares
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	595180	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-124748	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	713084	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	485739	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	267730	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14175	shares
	cpix	Increase Decrease In Current Operating Liabilities IncreaseDecreaseInCurrentOperatingLiabilities	-1705007	USD
	cpix	Increase Decrease In Current Operating Liabilities IncreaseDecreaseInCurrentOperatingLiabilities	640453	USD
CY2016Q4	cpix	Other Long Term Obligations Excluding Current Portion OtherLongTermObligationsExcludingCurrentPortion	1391484	USD
CY2017Q3	cpix	Other Long Term Obligations Excluding Current Portion OtherLongTermObligationsExcludingCurrentPortion	1634936	USD
CY2017Q1	cpix	Tax Benefit Windfall TaxBenefitWindfall	100000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001087294
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15748137	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	CUMBERLAND PHARMACEUTICALS INC
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8036611	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7921600	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7330127	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7205378	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	61224	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60708	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	562722	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1632920	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	239703	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1974194	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1241372	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	609572	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1811589	USD
CY2016Q4	us-gaap	Assets Assets	93404566	USD
CY2017Q3	us-gaap	Assets Assets	90351057	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	65545264	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	66082815	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38203059	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35546244	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34510330	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42018953	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2656815	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7508623	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16074176	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15781736	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16074176	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15781736	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	54643268	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	52585566	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	95488	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-234007	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-757240	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7228011	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	10678	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	39018	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14209	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	49923	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	106166	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-194989	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-743031	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-7178088	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1973948	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4353148	USD
CY2017Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2166353	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5216776	USD
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	8661621	USD
	us-gaap	Costs And Expenses CostsAndExpenses	24419880	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	12036310	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2017Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17000000	USD
CY2017Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15900000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	-907270	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	91109	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	428176	USD
	us-gaap	Costs And Expenses CostsAndExpenses	32678865	USD
CY2017Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1082924	USD
CY2017Q3	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	100000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	662689	USD
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4293963	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	3119930	USD
CY2017Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	0	USD
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1785057	USD
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6554158	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-907270	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1865575	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5817943	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-159282	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	22154176	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2090785	USD
CY2017Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21540316	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3031819	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	57192	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3822	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4196192	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	152680	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-393289	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-753418	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	29088	USD
	us-gaap	Interest Expense InterestExpense	77777	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	8902	USD
	us-gaap	Interest Expense InterestExpense	70646	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2283694	USD
CY2017Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2422225	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	5371729	USD
CY2017Q3	us-gaap	Inventory Net InventoryNet	5857468	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2810711	USD
CY2017Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3188240	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	USD
CY2017Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	600000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	51636	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	160248	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	94833	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	216849	USD
CY2016Q4	us-gaap	Liabilities Liabilities	20283747	USD
CY2017Q3	us-gaap	Liabilities Liabilities	25433027	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93404566	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90351057	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14792263	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15798091	USD
CY2016Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	4100000	USD
CY2017Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	8000000	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	15622111	USD
CY2017Q3	us-gaap	Marketable Securities MarketableSecurities	8055017	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	-127380	USD
CY2017Q3	us-gaap	Minority Interest MinorityInterest	-177303	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-786665	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1006143	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1619834	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6600632	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-250316	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98152	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	106166	USD
	us-gaap	Net Income Loss NetIncomeLoss	-194989	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-743031	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7178088	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10678	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-39018	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14209	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-49923	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	130132	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-475760	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-839349	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3178022	USD
CY2017Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	44100000	USD
CY2017Q3	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	3500000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2710967	USD
CY2017Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2945999	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2120742	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2253178	USD
CY2016Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	277324	USD
CY2017Q3	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	247003	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6755652	USD
CY2017Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7876491	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1879395	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2893857	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1554410	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	841647	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3643894	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2029414	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98275	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	172899	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	2000000	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	3900000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3676745	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9644592	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	95488	USD
	us-gaap	Profit Loss ProfitLoss	-234007	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-757240	USD
	us-gaap	Profit Loss ProfitLoss	-7228011	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	464454	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	474748	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	644662	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2029914	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	943162	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2921951	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	18604931	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	12509767	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	8791753	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	23944120	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	11196961	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	29500843	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3614714	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10585955	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6226438	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16174391	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	623504	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	849198	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	849198	USD
CY2010Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2011Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2012Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2013Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2015Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
CY2016Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000.0	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2906900	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	73248199	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	65095333	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73120819	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64918030	USD
CY2016Q4	us-gaap	Trading Securities TradingSecurities	15622111	USD
CY2017Q3	us-gaap	Trading Securities TradingSecurities	8055017	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	69140	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	48084	USD
CY2016Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	287126	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16504568	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16268579	shares
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15867159	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15973737	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16217442	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16268579	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15867159	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15973737	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEW PRODUCTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Totect </font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup> </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In late July 2017, the Company initiated distribution and sale of Totect (dexrazoxane hydrochloride) in the United States. This followed the FDA approval of the updated labeling and product manufacturer for the product. In late September 2017, the Company announced the launch of Totect promotion in the United States. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy. It treats anthracycline extravasation that occurs when the injected medication escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries or procedures and enables patients to continue their essential anti-cancer treatment.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparation for the Totect promotional launch, the Company completed the training of its sales and medical organization, stocked the product at select wholesalers serving hospitals, and recently introduced the product website. Totect is supported by Cumberland's hospital sales force. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company launched Totect during a national shortage of dexrazoxane. It's our second oncology support product and the second product licensed to it through the Strategic Alliance with Clinigen Group plc ("Clinigen").</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began generating revenue from the sale of Totect during the third quarter of 2017. Totect contributed </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> in net revenue for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cardioxane</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During August 2017, the Company also began shipments of Cardioxane (dexrazoxane hydrochloride, injection) which is used to support oncology patients from the cardiac complications associated with certain chemotherapeutic agents. These shipments were under a special, expedited clearance from the FDA to address the shortage of dexrazoxane in the United States.  The Company intends to make Cardioxane available in the United States through the end of 2017, until the current dexrazoxane drug shortage is alleviated. </font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is distributing Cardioxane through its Strategic Alliance with Clinigen who is supplying the product and has been selling it in several markets outside the United States.</font></div><div style="line-height:120%;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began generating revenue from the sale of Cardioxane during the third quarter of 2017. Cardioxane contributed </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> in net revenue for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) the projection of future taxable income for the realization of deferred tax assets.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-011224-index-headers.html	Edgar Link	pending
0001628280-17-011224-index.html	Edgar Link	pending
0001628280-17-011224.txt	Edgar Link	pending
0001628280-17-011224-xbrl.zip	Edgar Link	pending
cpix-20170930.xml	Edgar Link	completed
cpix-20170930.xsd	Edgar Link	pending
cpix-20170930_cal.xml	Edgar Link	unprocessable
cpix-20170930_def.xml	Edgar Link	unprocessable
cpix-20170930_lab.xml	Edgar Link	unprocessable
cpix-20170930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
loanagreementexhibit1034.htm	Edgar Link	pending
q32017-exhibit311.htm	Edgar Link	pending
q32017-exhibit312.htm	Edgar Link	pending
q32017-exhibit321.htm	Edgar Link	pending
q3201710q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2017 Q4 Form 10-Q Financial Statement

#000162828017011224 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX CUMBERLAND PHARMACEUTICALS INC Stock $cpix

2017 Q4 Form 10-Q Financial Statement

#000162828017011224 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CPIX
CUMBERLAND PHARMACEUTICALS INC Stock $cpix